Complete Genomics has developed a third-generation sequencing platform capable of delivering complete genome sequence data at an unprecedented level of throughput and low cost. The company is deploying this platform through its commercial-scale, fully automated human genome center and offering comprehensive human genome sequencing services to scientific researchers. This service will allow its customers to more efficiently characterize the full spectrum of genetic variants that exist in large numbers of human subjects. The ability to conduct large-scale human genome studies will enable researchers to further elucidate the genetic underpinnings of complex diseases and drug responses.

Complete Genomics has created a sequencing platform that is the combination of technology advancements in libraries, arrays, sequencing assay chemistry, instruments and software. These technologies have been integrated into a comprehensive system to enable large-scale complete human genome sequencing (Figure 1).

Figure 1: Complete Genomics Sequencing Technology Integration

The low reagent usage and high imaging efficiency of Complete Genomics sequencing platform enable sequencing of complete human genomes at a fraction of the cost of alternative approaches. The accuracy of Complete Genomics’ novel sequencing chemistry, combined with custom mapping and assembly techniques, enable the Company’s sequencing process (Figure 2) to resolve many of the complexities of the human genome, and thereby provide the high-quality human genome datasets required to advance understanding of complex diseases and drug responses

Furthermore, Complete Genomics is coupling its internally developed, high throughput sequencing instruments with an enterprise-class data center, to create the world’s largest commercial human genome sequencing center. This new facility will permit Complete Genomics to provide its customers with sequence reports on hundreds or thousands of human genomes efficiently and cost-effectively. With this approach, customers are not burdened with the operational, computational, and capital purchase costs of owning and operating the instruments, nor do they need to obtain the computing resources necessary for large-scale sequencing of complete human genomes.

Figure 2: Complete Genomics Sequencing Process